22nd Century Group Inc (XXII)

[brooklyn13]

History will not look kindly on Dr Gottlieb's tenure at the FDA. Both stronger opioids and nicotine delivery systems have flooded the market on his watch with zero regulatory pushback. Lots of talk, though.

Meanwhile, XXII has the patents. But it also has a mediocre management team and, as a result, is a lousy stock to own. Patience has not been its own reward around here.

We'll see how smirky Henry remains in the upcoming conference call.